Bioequivalence and safety evaluation of betahistine hydrochloride tablets: a randomized, open - label, crossover study
Test formulation is bioequivalent and well-tolerated to reference, supporting interchangeability. Limitations: small single-center sample, healthy subjects.
Authors
- Linling Li (ORCID: https://orcid.org/0000-0001-7767-7202)
- Fang Yao
- Yiyi Wang
- Zhixiang Pan (ORCID: https://orcid.org/0000-0002-0715-8973)
- Junchen Wang (ORCID: https://orcid.org/0000-0002-0916-9932)
- Tao Huang (ORCID: https://orcid.org/0000-0001-5897-4017)
- Yu Peng (ORCID: https://orcid.org/0009-0008-5014-3997)
- Qingqing Wang (ORCID: https://orcid.org/0000-0003-3256-9958)
- Yuehua Li (ORCID: https://orcid.org/0000-0002-2172-5874)
- Guan Liu (ORCID: https://orcid.org/0000-0001-7761-9512)
- Hegui Yan (ORCID: https://orcid.org/0009-0006-6019-7281)
- Dan Cao
Institutions
- Zhumadian Central Hospital (CN)
- Wuhan Pulmonary Hospital (CN)
- Toa Pharmaceutical (Japan) (JP)
Publication Details
- Journal
- Expert Opinion on Drug Metabolism & Toxicology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1080/17425255.2025.2598001
- Primary Topic
- Pharmacological Effects and Assays
- Type
- article
- Field-Weighted Citation Impact
- 0.00